Oncology
Aptamer therapeutics in Oncology can be configured in various ways:
Antagonist of protein-protein or receptor-ligand interactions
Aptamer–drug conjugates (ApDCs)
Aptamer-siRNA conjugates
Aptamer bi-specifics
Her3 Inhibitor Aptamer’s Intrinsic Anti-tumor Activity Can Be Augmented And Potency Improved By Conjugation to DM1
Aptamer (GRX1461) inhibits BXPC3 tumor growth in a dose dependent manner
Highest dose is equivalent to gemcitabine
Aptamer toxin conjugate (GRX1462) has improved potency
Highest dose completely inhibits tumor growth
Contact
© 2025 Guardian Therapeutics. All rights reserved.
Welcome to the Guardian Therapeutics and Band Therapeutics website. We do not use any cookies or other technologies on this website, except those that are strictly necessary to enable normal functioning of this web page. View our data protection statement.
Headquarters
Guardian Therapeutics
600 Suffolk St.
Suite 250
Lowell, MA 01854
General Inquiries:
info@guardian-rx.com
Business Development Inquiries: businessdevelopment@guardian-rx.com